The updated workflow approval suggests “that direct imaging guidance, such as ultrasound, may be used as an alternative to fluoroscopy,” the release states.
The change in labeling that has now been approved by the FDA “improves safety, and efficiency of cardiac ablation procedures,” Jasmina Brooks, president of Biosense Webster said in a statement. “As a result of this update, our teams can now proactively discuss the fluoroscopy alternative workflow with our customers to reinforce the benefits of the Biosense Webster portfolio of products.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
